Copyright
©The Author(s) 2020.
World J Gastroenterol. Jan 21, 2020; 26(3): 353-365
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.353
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.353
Case | Ref. | Age | Sex | Primary disease | Drug | Cycles until onset | Symptoms |
1 | Gelsomino et al[21] | 79 | M | NSCLC | Nivolumab | 4 | Itching, jaundice |
2 | Kawakami et al[19] | 64 | M | NSCLC | Nivolumab | 9 | Fever, abdominal discomfort |
3 | Kawakami et al[19] | 73 | F | NSCLC | Nivolumab | 6 | Fever, vomiting, abdominal discomfort, diarrhea |
4 | Kawakami et al[19] | 82 | F | NSCLC | Nivolumab | 12 | Fever, general fatigue |
5 | Kashima et al[22] | 63 | M | NSCLC | Nivolumab | 24 | Epigastric pain, soft stool |
6 | Doherty et al[23] | 49 | F | Melanoma | Pembrolizumab | 1 | Jaundice |
7 | Doherty et al[23] | 59 | F | Melanoma | Nivolumab | 3 | None (liver dysfunction) |
8 | Doherty et al[23] | 76 | M | epithelioid mesothelioma | Pembrolizumab | 1 | Jaundice |
9 | Cho et al[24] | 69 | M | NSCLC | Avelumab | 21 | Right upper abdominal discomfort |
10 | Hamoir et al[25] | 71 | M | NSCLC | Nivolumab | NA (11 mo) | None (liver dysfunction) |
11 | Kuraoka et al[26] | 69 | M | NSCLC | Nivolumab | 3 | Pruritic rash, liver dysfunction |
12 | Ogawa et al[27] | 73 | M | Melanoma | Pembrolizumab | NA (3 mo) | None (liver dysfunction) |
13 | Kono et al[28] | 69 | F | GC | Nivolumab | 2 | Jaundice |
14 | Noda-Narita et al[29] | 57 | F | NSCLC | Nivolumab | NA (12 mo) | Abdominal pain |
15 | Sawada et al[30] | 76 | M | GC | Nivolumab | 4 | None (liver dysfunction) |
16 | Tallec et al[31] | 56 | F | NSCLC | Nivolumab | 16 (9 mo) | Myalgia, skin thickening |
17 | Oda et al[32] | 43 | M | GC | Nivolumab | 1 | Fever, tachycardia, appetite loss, malaise |
18 | Koya et al[33] | 66 | M | SCLC | Pembrolizumab | 5 | Epigastric pain |
19 | Fouchard et al[34] | 52 | M | NSCLC | Nivolumab | 8 | Abdominal pain |
20 | Fouchard et al[34] | NA | M | NSCLC | Durvalumab (+ tremelimumab) | 4 | Fever, abdominal pain |
21 | Fouchard et al[34] | 61 | M | NSCLC | Pembrolizumab | 17 | None (liver dysfunction) |
22 | Cǎlugǎreanu et al[35] | 43 | F | Melanoma | Nivolumab | 27 | Epigastralgia, anorexia, |
23 | Anderson et al[36] | 67 | M | NSCLC | Nivolumab | 8 | Right upper abdominal pain |
24 | Zen et al[37] | 68 | M | NSCLC | Pembrolizumab | NA (5.5 mo) | Abdominal pain, vomiting |
25 | Zen et al[40] | 67 | M | NSCLC | Pembrolizumab | NA (1 mo) | Fever, malaise |
26 | Our case | 61 | M | BC | Pembrolizumab | 5 | Fever |
27 | Our case | 89 | M | BC | Pembrolizumab | 4 | None (liver dysfunction) |
28 | Our case | 63 | M | NSCLC | Pembrolizumab | 7 | None (liver dysfunction) |
29 | Our case | 55 | M | NSCLC | Nivolumab | 11 | Abdominal pain |
30 | Our case | 81 | F | NSCLC | Nivolumab | 25 | Backache |
31 | Our case | 82 | F | NSCLC | Nivolumab | 2 | None (liver dysfunction) |
- Citation: Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365
- URL: https://www.wjgnet.com/1007-9327/full/v26/i3/353.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i3.353